JP7532361B2 - 酸化ストレスに関連付けられる皮膚疾患及び皮膚老化を処置するための組成物ならびに酸化ストレスに関連付けられる皮膚疾患の診断。 - Google Patents

酸化ストレスに関連付けられる皮膚疾患及び皮膚老化を処置するための組成物ならびに酸化ストレスに関連付けられる皮膚疾患の診断。 Download PDF

Info

Publication number
JP7532361B2
JP7532361B2 JP2021526737A JP2021526737A JP7532361B2 JP 7532361 B2 JP7532361 B2 JP 7532361B2 JP 2021526737 A JP2021526737 A JP 2021526737A JP 2021526737 A JP2021526737 A JP 2021526737A JP 7532361 B2 JP7532361 B2 JP 7532361B2
Authority
JP
Japan
Prior art keywords
roxp
acnes
skin
subject
strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526737A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020099663A5 (https=
JP2022507616A5 (https=
JP2022507616A (ja
Inventor
ロード，ロルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
S Biomedic NV
Original Assignee
S Biomedic NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Biomedic NV filed Critical S Biomedic NV
Publication of JP2022507616A publication Critical patent/JP2022507616A/ja
Publication of JPWO2020099663A5 publication Critical patent/JPWO2020099663A5/ja
Publication of JP2022507616A5 publication Critical patent/JP2022507616A5/ja
Application granted granted Critical
Publication of JP7532361B2 publication Critical patent/JP7532361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7004—Stress
    • G01N2800/7009—Oxidative stress

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
JP2021526737A 2018-11-16 2019-11-15 酸化ストレスに関連付けられる皮膚疾患及び皮膚老化を処置するための組成物ならびに酸化ストレスに関連付けられる皮膚疾患の診断。 Active JP7532361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18206646 2018-11-16
EP18206646.4 2018-11-16
PCT/EP2019/081546 WO2020099663A1 (en) 2018-11-16 2019-11-15 Compositions for treating oxidative stress-associated skin diseases and skin ageing and diagnosis of oxidative stress-associated skin diseases

Publications (4)

Publication Number Publication Date
JP2022507616A JP2022507616A (ja) 2022-01-18
JPWO2020099663A5 JPWO2020099663A5 (https=) 2022-11-16
JP2022507616A5 JP2022507616A5 (https=) 2022-11-16
JP7532361B2 true JP7532361B2 (ja) 2024-08-13

Family

ID=64331864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526737A Active JP7532361B2 (ja) 2018-11-16 2019-11-15 酸化ストレスに関連付けられる皮膚疾患及び皮膚老化を処置するための組成物ならびに酸化ストレスに関連付けられる皮膚疾患の診断。

Country Status (12)

Country Link
US (1) US20220000762A1 (https=)
EP (1) EP3880304B8 (https=)
JP (1) JP7532361B2 (https=)
KR (1) KR102913696B1 (https=)
CN (1) CN113038959B (https=)
AU (1) AU2019380669B2 (https=)
BR (1) BR112021008496A2 (https=)
CA (1) CA3118524A1 (https=)
ES (1) ES2994459T3 (https=)
MX (1) MX2021005755A (https=)
PL (1) PL3880304T3 (https=)
WO (1) WO2020099663A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3025685T3 (en) 2014-06-17 2025-06-09 Crown Laboratories Inc Genetically modified bacteria and methods for genetic modification of bacteria
EP3285872A4 (en) 2015-04-20 2019-02-20 S-Biomedic NV METHOD AND COMPOSITIONS FOR CHANGING THE COMPOSITION OF SKIN MICROBIOMA WITH COMPLEX MIXTURES OF BACTERIAL BARS
WO2017147507A1 (en) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Skin probiotic formulation
KR102584057B1 (ko) 2016-10-19 2023-09-27 에스-바이오메딕 엔브이 박테리아 균주의 복합 혼합물을 사용하여 피부 마이크로바이옴의 조성을 변경하기 위한 방법 및 조성물
CA3183350A1 (en) 2020-06-23 2021-12-30 Thomas M. Hitchcock Probiotic skin formulations
CN116940330A (zh) * 2020-12-21 2023-10-24 南洋理工大学 短链脂肪酸作为去屑剂的用途
CN113219097B (zh) * 2021-01-15 2022-06-24 杭州海关技术中心 婴幼儿配方奶粉中肉碱对映体拆分和测定方法
CA3239122A1 (en) * 2021-12-17 2023-06-22 S-Biomedic A freeze-dried composition and preparation thereof
EP4197523A1 (en) * 2021-12-17 2023-06-21 DSM IP Assets B.V. A freeze-dried composition and preparation thereof
KR20240135644A (ko) * 2022-01-12 2024-09-11 에스-바이오메딕 엔브이 스킨 케어 조성물 및 이의 용도
CN115165819B (zh) * 2022-05-27 2024-08-09 天津科技大学 一种快速定量分析芦丁的荧光分子印迹光子晶体凝胶条的制备方法及应用
CN120173837B (zh) * 2025-05-21 2025-12-05 杭州微致生物科技有限公司 痤疮丙酸杆菌vb208基因编辑方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073651A1 (en) 2016-10-19 2018-04-26 S-Biomedic Nv Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
JP2011037764A (ja) * 2009-08-11 2011-02-24 Shiseido Co Ltd 皮膚外用剤、美白剤、抗酸化剤および抗老化剤
FR2954140A1 (fr) * 2009-12-17 2011-06-24 Oreal Compositions cosmetiques ou dermatologiques a base de bacteriocines et de prebiotiques
ITPR20110035A1 (it) 2011-05-06 2012-11-07 Bormioli Rocco & Figlio Spa Capsula.
CN104364394B (zh) * 2012-03-17 2019-02-22 加州大学评议会 痤疮的快速诊断和个体化治疗
ITUA20162141A1 (it) 2016-03-31 2017-10-01 Bormioli Pharma Spa Capsula di chiusura
IT201600097495A1 (it) 2016-09-28 2018-03-28 Bormioli Pharma S R L Capsula con struttura di contenimento e rilascio di un prodotto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073651A1 (en) 2016-10-19 2018-04-26 S-Biomedic Nv Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIZEM ERTURK; ET AL，HIGHLY SENSITIVE DETECTION AND QUANTIFICATION OF THE SECRETED BACTERIAL BENEVOLENCE 以下備考，PLOS ONE，2018年03月，VOL:13,NR:3，PAGE(S):E0193754(1-13)，https://doi.org/10.1371/journal.pone.0193754，FACTOR ROXP USING A CAPACITIVE BIOSENSOR: A POSSIBLE EARLY DETECTION SYSTEM FOR OXIDATIVE 以下省略
MARIA ALLHORN; ET AL，A NOVEL ENZYME WITH ANTIOXIDANT CAPACITY PRODUCED BY THE UBIQUITOUS SKIN COLONIZER 以下備考，SCIENTIFIC REPORTS，2016年11月02日，VOL:6, NR:1，PAGE(S):36412(1-12)，https://dx.doi.org/10.1038/srep36412，PROPIONIBACTERIUM ACNES

Also Published As

Publication number Publication date
EP3880304B8 (en) 2024-11-20
EP3880304A1 (en) 2021-09-22
KR102913696B1 (ko) 2026-01-16
MX2021005755A (es) 2021-08-11
AU2019380669B2 (en) 2025-01-30
EP3880304C0 (en) 2024-10-16
WO2020099663A1 (en) 2020-05-22
KR20210094576A (ko) 2021-07-29
PL3880304T3 (pl) 2025-03-03
US20220000762A1 (en) 2022-01-06
EP3880304B1 (en) 2024-10-16
JP2022507616A (ja) 2022-01-18
CA3118524A1 (en) 2020-05-22
BR112021008496A2 (pt) 2021-08-10
CN113038959B (zh) 2024-09-13
CN113038959A (zh) 2021-06-25
AU2019380669A1 (en) 2021-05-20
ES2994459T3 (en) 2025-01-24

Similar Documents

Publication Publication Date Title
JP7532361B2 (ja) 酸化ストレスに関連付けられる皮膚疾患及び皮膚老化を処置するための組成物ならびに酸化ストレスに関連付けられる皮膚疾患の診断。
Al-Madboly et al. Purification, characterization, identification, and anticancer activity of a circular bacteriocin from Enterococcus thailandicus
Gaitanis et al. The Malassezia genus in skin and systemic diseases
Sánchez-Pellicer et al. Rosacea, microbiome and probiotics: the gut-skin axis
Ikonomopoulou et al. Gomesin inhibits melanoma growth by manipulating key signaling cascades that control cell death and proliferation
Yang et al. Role of two-component system response regulator bceR in the antimicrobial resistance, virulence, biofilm formation, and stress response of group B Streptococcus
EP2178904B1 (en) Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
Yang et al. GSTpi regulates VE-cadherin stabilization through promoting S-glutathionylation of Src
Soltani et al. In vitro assessment of skin sensitization, irritability and toxicity of bacteriocins and reuterin for possible topical applications
Feng et al. A non-bactericidal cathelicidin with antioxidant properties ameliorates UVB-induced mouse skin photoaging via intracellular ROS scavenging and Keap1/Nrf2 pathway activation
JP7262445B2 (ja) バチルス・コアグランスを含有する汚染防止組成物
CN110167955A (zh) 细菌抑制剂
Sannasimuthu et al. Peroxiredoxin of Arthrospira platensis derived short molecule YT12 influences antioxidant and anticancer activity
JP2015504417A (ja) ジンジパイン阻害プロペプチド
Liu et al. The antimicrobial peptide Abaecin alleviates colitis in mice by regulating inflammatory signaling pathways and intestinal microbial composition
Wan et al. Characterization of a novel streptococcal heme-binding protein SntA and its interaction with host antioxidant protein AOP2
HK40049609A (en) Compositions for treating oxidative stress-associated skin diseases and skin ageing
HK40049609B (en) Compositions for treating oxidative stress-associated skin diseases and skin ageing
Hu et al. The Rab1 GTPase of Sciaenops ocellatus modulates intracellular bacterial infection
Ashbee et al. Malassezia
Mohanan et al. Moisturizing and antioxidant factors of skin barrier restoring cream with shea butter, silkflo and vitamin E in human keratinocyte cells
Mahana et al. Fasciola gigantica enolase is a major component of worm tegumental fraction protective against sheep fasciolosis
KR20200053068A (ko) C-펩타이드를 유효성분으로 포함하는 미세먼지에 대한 피부보호용 화장료 조성물
Boff et al. Staphylococcus aureus LukMF′ targets neutrophils to promote skin and soft tissue infection
Pancarte et al. Strengthening the Skin Barrier by Using a Late Cornified Envelope 6A‐Derived Biomimetic Peptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7532361

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150